Results 121 to 130 of about 464 (144)

Efficacy and Safety of Lotilaner Ophthalmic Solution (0.25%) for the Treatment of Demodex Blepharitis: A GRADE Assessed Systematic Review and Meta-Analysis of Observational & Experimental Studies

American Journal of Ophthalmology
PurposeThis review aims to assess the safety and efficacy of Lotilaner in the treatment of Demodex Blepharitis.DesignSystematic Review and Meta-AnalysisBackgroundDemodex blepharitis is a common eye condition that arises from Demodex mites infestation ...
Abdulqadir J Nashwan, Arsalan Nadeem, Abdullah Ahmed   +2 more
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Chrysomya bezziana (Diptera: Calliphoridae) infestation in two Malaysian cats treated with oral lotilaner

Veterinary Dermatology, 2020
The most common fly species associated with screwworm myiasis in Southeast Asia is Chrysomya bezziana (Ch. bezziana), the Old‐World screwworm. Treatment of screwworm myiasis in cats traditionally has comprised subcutaneous injection of ivermectin or oral administration of nitenpyram, combined with aggressive tissue debridement and larval removal under ...
Hock Siew Han, Lynn Yasmin
openaire   +2 more sources

Lotilaner (Xdemvy) for Demodex Blepharitis

The Medical Letter on Drugs and Therapeutics
The FDA has approved a 0.25% ophthalmic solution of the ectoparasiticide lotilaner (Xdemvy – Tarsus) for treatment of Demodex blepharitis. Lotilaner is the first drug to be approved in the US for this indication.
openaire   +2 more sources

Use of lotilaner in opossum (Didelphis marsupialis) infested with Ornithonyssus spp.

Journal of Exotic Pet Medicine, 2021
Jesús Dueñas Muñoz, Ahtziri Yahaira Santillán Sánchez, Paola Rebolledo Prieto, Ariadna Flores Ortega, Camilo Romero Núñez, Cecilia López Márquez   +5 more
openaire   +1 more source

Lotilaner Ophthalmic Solution 0.25% for Demodex Blepharitis: Randomized, Vehicle-Controlled, Multicenter, Phase 3 Trial (Saturn-2)

Ophthalmology, 2023
Elizabeth Yeu, Paul M Karpecki, Ian Benjamin Gaddie   +2 more
exaly  

Lotilaner

2021
openaire   +1 more source

Safety and Efficacy of Lotilaner Ophthalmic Solution, 0.25% for the Treatment of Blepharitis Due to Demodex Infestation: A Randomized, Controlled, Double-Masked Clinical Trial

Contact Lens and Anterior Eye, 2022
Roberto Gonzalez-Salinas, Hugo Quiroz-Mercado, Stephanie Baba   +2 more
exaly  

Treatment of Demodex Blepharitis: A Prospective, Randomized, Controlled, Double-Masked Clinical Trial Comparing Topical Lotilaner Ophthalmic Solution, 0.25% Eyedrops to Vehicle

Ocular Immunology and Inflammation, 2023
Roberto Gonzalez-Salinas, Hugo Quiroz-Mercado, Stephanie Baba   +2 more
exaly  

Collarette Elimination and Demodex Mite Eradication With Topical Lotilaner Ophthalmic Solution, 0.25%

Journal of Ocular Pharmacology and Therapeutics, 2021
Roberto Gonzalez-Salinas, Hugo Quiroz-Mercado, Stephanie Baba   +2 more
exaly  

XdemvyTM (Lotilaner Ophthalmic Solution) 0.25% Topical Solution for the Treatment of Demodex Blepharitis.

Skinmed
XdemvyTM (lotilaner ophthalmic solution) 0.25% topical solution was recently approved for the treatment of Demodex blepharitis in adults aged ≥18 years. As an antiparasitic agent, lotilaner selectively inhibits gamma-aminobutyric acid chloride channels specific to the parasite and induces spastic paralysis, leading to death of Demodex blepharitis mites.
Aditya K, Gupta, Avantika, Mann, Kimberly, Vincent, William, Abramovits   +3 more
openaire   +1 more source